Applied Aerospace & Defense, Inc.
Moat Score — Aadi Bioscience, Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Aadi holds FDA orphan drug exclusivity as the sole approved therapy for advanced malignant PEComa, plus patents covering its albumin-bound nab-sirolimus formulation. This regulatory and IP combination creates a real, if narrow, monopoly in its lead indication. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small-cap specialty biopharma with a single manufactured product, Aadi has no meaningful scale or cost advantage versus larger oncology manufacturers; its cost base is largely fixed R&D and a lean commercial organization. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | With no competing approved therapy for advanced malignant PEComa, Aadi can price FYARRO at typical specialty-oncology levels, and payers have limited alternative options for this life-threatening rare cancer, supporting strong list pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products like FYARRO do not benefit from network effects; the value of the drug to one patient or physician is unaffected by how many others use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a physician establishes a treatment regimen and patients respond, there is some inertia against switching, but with no other approved PEComa therapy to switch from or to, true switching-cost dynamics are limited today. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The addressable PEComa population is so small that it likely cannot support multiple competing branded therapies, giving Aadi an efficient-scale-style protection: the market may simply be too niche to attract large pharma competition. |